Wellington Management Group
BCRX icon

Wellington Management Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wellington Management Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Buy
293,925
+195,042
+197% +$1.76M ﹤0.01% 1544
2026
Q1 		$941K Buy
98,883
+12,363
+14% +$96K ﹤0.01% 1686
2025
Q4 		$675K Sell
86,520
-7,010
-7% -$50.7K ﹤0.01% 1782
2025
Q3 		$710K Buy
93,530
+6,752
+8% +$56.2K ﹤0.01% 1837
2025
Q2 		$778K Sell
86,778
-4,570
-5% -$42.6K ﹤0.01% 1752
2025
Q1 		$685K Buy
91,348
+2,291
+3% +$18.5K ﹤0.01% 1777
2024
Q4 		$670K Sell
89,057
-18,763
-17% -$142K ﹤0.01% 1787
2024
Q3 		$819K Buy
+107,820
New +$820K ﹤0.01% 1745
2020
Q1 		– Sell
-22,708
Closed -$78K – 1915
2019
Q4 		$78K Sell
22,708
-5,420
-19% -$13.6K ﹤0.01% 1997
2019
Q3 		$80K Sell
28,128
-6,890
-20% -$21.4K ﹤0.01% 2008
2019
Q2 		$133K Hold
35,018
– – ﹤0.01% 2028
2019
Q1 		$285K Buy
+35,018
New +$300K ﹤0.01% 1969
2017
Q2 		– Sell
-202,317
Closed -$1.7M – 2204
2017
Q1 		$1.7M Buy
+202,317
New +$1.41M ﹤0.01% 1779
2016
Q3 		– Sell
-256,120
Closed -$727K – 2181
2016
Q2 		$727K Sell
256,120
-1,240,739
-83% -$3.85M ﹤0.01% 1846
2016
Q1 		$4.24M Sell
1,496,859
-5,973,580
-80% -$26.5M ﹤0.01% 1405
2015
Q4 		$77.1M Sell
7,470,439
-31,497
-0.4% -$313K 0.02% 551
2015
Q3 		$85.5M Buy
7,501,936
+520,365
+7% +$6.94M 0.02% 492
2015
Q2 		$104M Sell
6,981,571
-38,712
-0.6% -$440K 0.03% 477
2015
Q1 		$63.4M Sell
7,020,283
-368,990
-5% -$3.82M 0.02% 662
2014
Q4 		$89.9M Buy
7,389,273
+1,529,847
+26% +$16.9M 0.02% 548
2014
Q3 		$57.3M Buy
5,859,426
+510,081
+10% +$6.25M 0.02% 674
2014
Q2 		$68.2M Buy
5,349,345
+1,329,584
+33% +$12.9M 0.02% 642
2014
Q1 		$42.5M Sell
4,019,761
-771,469
-16% -$8.23M 0.01% 795
2013
Q4 		$36.4M Buy
4,791,230
+2,159,640
+82% +$13.7M 0.01% 827
2013
Q3 		$19.2M Buy
+2,631,590
New +$13.3M 0.01% 1014

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Wellington Management Group's BCRX Position: Q2 2026 in Review

Wellington Management Group increased its BioCryst Pharmaceuticals (BCRX) stake by 197% in Q2 2026, buying an estimated $1.76M and bringing the position to 293,925 shares worth $2.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

Wellington Management Group first reported a position in BCRX in Q3 2013 and has held it in 25 quarters since. The position peaked at $104M in Q2 2015. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Wellington Management Group held 293,925 shares of BioCryst Pharmaceuticals worth $2.94M as of Q2 2026.
  • Wellington Management Group bought 195,042 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.76M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1544 holding.
  • Wellington Management Group first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 25 quarters since.
  • Wellington Management Group's BioCryst Pharmaceuticals position peaked at $104M in Q2 2015.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.